Glucocorticoids are used to treat respiratory dysfunction associated with premature birth but have been shown to cause neurodevelopmental deficits when used therapeutically. Recently, we established that acute glucocorticoid exposure at clinically relevant doses produces neural progenitor cell apoptosis in the external granule layer of the developing mouse cerebellum and permanent decreases in the number of cerebellar neurons. As the cerebellum naturally matures and neurogenesis is no longer needed, the external granule layer decreases proliferation and permanently disappears during the second week of life. At this same time, corticosterone (the endogenous rodent glucocorticoid) release increases and a glucocorticoid-metabolizing enzyme that protects the external granule layer against glucocorticoid receptor stimulation (11β-Hydroxysteroid-Dehydrogenase-Type 2; HSD2) naturally disappears. Here we show that HSD2 inhibition and raising corticosterone to adult physiological levels both can independently increase neural progenitor cell apoptosis in the neonatal mouse. Conversely, glucocorticoid receptor antagonism decreases natural physiological apoptosis in this same progenitor cell population suggesting that endogenous glucocorticoid stimulation may regulate apoptosis in the external granule layer. We also found that glucocorticoids which HSD2 can effectively metabolize generate less external granule layer apoptosis than glucocorticoids this enzyme is ineffective at breaking down. This finding may explain why glucocorticoids that this enzyme can metabolize are clinically effective at treating respiratory dysfunction yet seem to produce no neurodevelopmental deficits. Finally, we demonstrate that both acute and chronic glucocorticoid exposures produce external granule layer apoptosis but without appropriate control groups this effect becomes masked. These results are discussed in terms of their implications for glucocorticoid therapy and neurodevelopment during the perinatal period.
Introduction
Recent clinical research has found that the postnatal use of glucocorticoid (GC) therapy can cause permanent neuromotor and cognitive deficits (Yeh et al., 2004) leading to the recommendation that this drug regimen not be used outside of placebo controlled clinical trials (Committee on Fetus and Newborn, 2002) . Despite these concerns, GC therapy continues to be used throughout the world. For example, approximately 10% of prematurely born infants in North America and Europe still receive this treatment (Onland et al., 2009) . Additionally, while prenatal GC therapy (which is given to approximately 7-10% of all pregnant women in North America and Europe; Matthews et al., 2004) has generally been considered safe, more recent clinical research has shown that treatment regimens using multiple exposure produce decreased head circumference (a proxy measurement for brain size; Amaral et al., 2008) , length, and weight in neonates at birth (Murphy et al., 2008) . Unfortunately, despite the large percentage of humans exposed to this controversial therapy (Eventov-Friedman and Shinwell, 2008) , surprisingly little is known about how GC exposure can iatrogenically produce the neurodevelopmental deficits seen clinically.
In previous research, we discovered that exposure to clinically relevant doses of dexamethasone (DEX) produced rapid neural progenitor cell (NPC) apoptosis (programmed cell death) in the external granule layer (EGL) of the immature mouse cerebellum (Noguchi et al., 2008) . The window of vulnerability for this toxicity in the mouse corresponds to all time points during which perinatal GC therapy would occur in the human (Noguchi et al., 2008) . One curious aspect of this toxicity is that it is selectively confined to the NPCs contained within the outer EGL, a transient proliferative region occupying the most superficial cerebellar layer. The EGL produces new neurons in its outermost layer that first congregate and mature in the inner EGL before migrating through the molecular and Purkinje cell layers to populate the internal granule layer as neurons (Fig. 1A) . The 
